One group received 0.4 μg/ml PCSK9, representing the PCSK9 concentrations measured post-myocardial infarction (MI) in the plasma and in different areas of the heart, while another group received 2.0 μg/ml PCSK9, corresponding to the PCSK9 concentrations measured in plasma following weekly Alirocumab injections. The gene discussed is PCSK9; the disease is myocardial infarction.